The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from ...

Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer ...

Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider ...

To further refine risk stratification, other mental health conditions or diagnostic tools should be considered, according to ...

Pfizer is looking to sell about 700 million ordinary shares in Haleon, its bookrunner J.P. Morgan said on Tuesday, lowering ...

The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor returns but remains wary over ...

January is a big time for drugmakers to hike prices. This year saw higher prices for 575 medications so far, including ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

Pfizer divests $3.05 billion of Haleon shares, cutting its stake to 7.3% in a strategic shift to refocus on core ...

These companies headline a $1.4 trillion industry, have staying power, and will pay you well to hold their stock.

Pfizer Inc. is offering around 700 million shares in Haleon Plc, representing a roughly 7.7% stake in the maker of Sensodyne ...

Vaxcyte's robust financial position supports its strategic flexibility and extended timelines. Read more to see why I rate ...